aap's full year 2011 sales on product-level totalled EUR 29.2 million (+6%) and Q4 sales increased by 9% to EUR 8.2 million
(Thomson Reuters ONE) -
aap Implantate AG /
aap's full year 2011 sales on product-level totalled EUR 29.2 million (+6%) and
Q4 sales increased by 9% to EUR 8.2 million
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Preliminary figures indicate that aap Implantate AG, a medical technology
company listed in the Frankfurt Stock Exchange's Prime Standard segment,
achieved sales at product level of EUR 8.2 million (previous year: EUR 7.5
million) in the fourth quarter of 2011; this results in a 9% sales increase on
the previous year's fourth quarter. In the financial year 2011, aap increased
its sales on product-level by 6% compared to the previous year to EUR 29.2
million from EUR 27.5 million.
In the fourth quarter, sales were generated by the first major shipments of our
innovative LOQTEQ® system to international customers. In addition, aap signed a
bone cement development contract with a globally active orthopaedic company.
Due to two fundamental factors aap did not quite succeed in achieving its
ambitious sales targets for the financial year 2011. For one, a major shipment
of products from our cannulated screws segment to the United States was delayed
in the fourth quarter. For another, developments in the orthopaedics segment did
not live up to our expectations. Sales in this segment are on a par with the
previous year.
2011 - Results and analysis
Overall sales in the financial year 2011 totalled EUR 29.2 million (previous
year EUR 28.4 million), leading to 3% sales growth on the previous year. Product
sales in the second half of 2011 were nearly 6% up on the first half at EUR
15.0 million.
aap's growth drivers in 2011 were its core business cement and cementing
techniques as well as trauma. In Nijmegen the center of excellence for contract
manufacturing also developed positively in 2011 and exceeded our expectations.
aap achieved the following further targets it had set itself in its management
agenda for 2011. It boosted its business activities in the US market most
successfully, increasing sales by over 30%. Contract manufacturing at the
Nijmegen site also increased substantially: Over the past year Nijmegen has
signed contracts with three new customers. The innovative LOQTEQ® product line
was launched both nationally and internationally, generating national sales
since the third quarter and its first international sales in the fourth quarter.
The establishment of a uniform IT infrastructure across the group has been
almost completed. Nearly all aap employees now work in an uniform IT
environment.
2012 - Outlook
In the financial year 2012 aap will further optimize the areas customers,
innovation, finance and organization, which are to be outlined in our 2012
Management Agenda. The Management Board anticipates sales growth at product
level of 10% for 2012.
With a positive cash EBIT (EBIT excluding internally produced and capitalized
assets and depreciation thereof) at product level, aap aims to finance its
growth internally in 2012. The principles of profitable growth are also to be
further applied in 2012 and the relative share of working capital as a
proportion of sales is to be reduced. Another objective is to further improve
aap's Freshness Index.
At the beginning of January, aap signed a letter of intend with the US sales
specialist Bioscompass, Inc. on the sale of patent and related rights for the
anti-adhesion product Adcon®. aap continues to be the product's manufacturer and
supplier.
As part of its ongoing focus on the trauma and cement and cementing technique
segments, aap is continuing to look into possibilities of additional product
divestments.
aap plans to publish the full annual report for 2011 on March 30, 2012.
This release contains forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
__________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for the areas Ortho/Trauma/Spine. Its product
portfolio includes bone cements, bone graft substitutes, antibiotic carriers,
and implants for fracture healing and joint replacement. In addition to its
Berlin HQ the Company has sites in Dieburg near Frankfurt am Main and Nijmegen
in the Netherlands. aap Implantate AG stock has been listed in the Prime
Standard segment of the Frankfurt Stock Exchange since May 16, 2003.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9290, m.heydrich(at)aap.de
For more details please visit www.aap.de
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1577352]
Unternehmensinformation / Kurzprofil:
Datum: 13.01.2012 - 11:25 Uhr
Sprache: Deutsch
News-ID 103897
Anzahl Zeichen: 6788
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap's full year 2011 sales on product-level totalled EUR 29.2 million (+6%) and Q4 sales increased by 9% to EUR 8.2 million"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
